Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.590
+0.020 (1.27%)
Dec 20, 2024, 4:00 PM EST - Market closed
Werewolf Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 3.39 | 19.94 | 16.4 | - | - | - |
| Revenue Growth (YoY) | -86.84% | 21.60% | - | - | - | - |
| Cost of Revenue | 47.49 | 38.91 | 50.96 | 33.98 | - | - |
| Gross Profit | -44.1 | -18.96 | -34.56 | -33.98 | - | - |
| Selling, General & Admin | 22.11 | 21.54 | 21.5 | 16.11 | 5.76 | 3.6 |
| Research & Development | - | - | - | - | 16.64 | 6.34 |
| Operating Expenses | 22.11 | 21.54 | 21.5 | 16.11 | 22.4 | 9.94 |
| Operating Income | -66.21 | -40.5 | -56.06 | -50.09 | -22.4 | -9.94 |
| Interest Expense | -4.4 | -3.14 | - | - | - | -0.37 |
| Interest & Investment Income | 7.34 | 7.42 | 1.91 | 0.1 | 0.06 | - |
| Other Non Operating Income (Expenses) | 1.7 | -1.14 | 0.34 | - | 7.3 | 0.06 |
| Pretax Income | -62.12 | -37.37 | -53.81 | -49.98 | -15.04 | -10.25 |
| Net Income | -62.12 | -37.37 | -53.81 | -49.98 | -15.04 | -10.25 |
| Preferred Dividends & Other Adjustments | - | - | - | 151.94 | 13.18 | 7.98 |
| Net Income to Common | -62.12 | -37.37 | -53.81 | -201.93 | -28.22 | -18.23 |
| Shares Outstanding (Basic) | 41 | 36 | 29 | 18 | 1 | 1 |
| Shares Outstanding (Diluted) | 41 | 36 | 29 | 18 | 1 | 1 |
| Shares Change (YoY) | 20.96% | 23.50% | 56.40% | 1736.32% | 57.27% | - |
| EPS (Basic) | -1.50 | -1.05 | -1.86 | -10.94 | -28.08 | -28.53 |
| EPS (Diluted) | -1.53 | -1.05 | -1.86 | -10.94 | -28.08 | -28.53 |
| Free Cash Flow | -46.85 | -33.38 | -44.21 | -43.37 | -19.18 | -9.81 |
| Free Cash Flow Per Share | -1.13 | -0.94 | -1.53 | -2.35 | -19.09 | -15.35 |
| Gross Margin | - | -95.09% | -210.69% | - | - | - |
| Operating Margin | -1955.35% | -203.09% | -341.78% | - | - | - |
| Profit Margin | -1834.55% | -187.37% | -328.09% | - | - | - |
| Free Cash Flow Margin | -1383.64% | -167.38% | -269.54% | - | - | - |
| EBITDA | -64.38 | -38.74 | -54.95 | -49.87 | -22.25 | -9.91 |
| EBITDA Margin | - | -194.25% | - | - | - | - |
| D&A For EBITDA | 1.83 | 1.76 | 1.1 | 0.22 | 0.15 | 0.03 |
| EBIT | -66.21 | -40.5 | -56.06 | -50.09 | -22.4 | -9.94 |
| EBIT Margin | - | -203.09% | - | - | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.